The recommended dose of Enbrel® for patients with JIA is based on weight1:
Discontinuation of treatment should be considered in JIA patients who show no response after 4 months. The 10 mg vial strength may be more appropriate for children below the weight of 25 kg1
Adapted from Enbrel® LPD. Version LPDENB062021.
Discontinuation of treatment should be considered in patients with JIA who show no response after 4 months.1
BIW, twice a week; FDA, Food and Drug Administration; JIA, juvenile idiopathic arthritis; QW, once a week; RCT, randomised controlled trial; TNF, tumour necrosis factor; TNFR, tumour necrosis factor receptor.
Please click the Prescribing Information link to view the safety and adverse events information of Enbrel®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-ENB-IND-0814 August 2022
Enbrel® is a soluble tumour necrosis factor receptor fusion protein
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022